Banc of America Lowers Intermune to 'Neutral'

Analyst Michael King says the drugmaker's shares reached his $24 target, and he sees limited upside

Banc of America downgraded Intermune (ITMN ) to neutral from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.